Incidence, prevalence and survival of neuroendocrine neoplasia 1995–2018

#3544

Introduction: Incidence of neuroendocrine neoplasia (NEN) is rising worldwide. England's National Cancer Registry and Analysis Service (NCRAS) records more than 99.5% of tumors. Recent improvements to the registry allow NEN to be analysed with greater accuracy.

Aim(s): To calculate overall incidence and prevalence, site-specific survival with multivariable analysis and survival over time of NEN in England from 1995-2018.

Materials and methods: Data was obtained from NCRAS via Public Health England. Goblet cell carcinoma, Merkel and adenoneuroendocrine were excluded from survival analysis. NEN before 2012 were excluded from site survival analysis group due historic coding and recording variability. Tumors were grouped as neuroendocrine tumor(NET) or neuroendocrine carcinoma(NEC) based on morphology codes. Large and small cell were included within NEC.

Conference:

Presenting Author: White B

Authors: White B, Chandrakumaran K, Wong K, Rous B, Bouvier C,

Keywords: epidemiology, incidence, prevalence, survival,